[Emerging disease-modifying therapies for multiple sclerosis]

研究成果: Article

抄録

Multiple sclerosis(MS) is an inflammatory demyelinating disease of the central nervous system with yet undetermined etiology. The incidence of MS is rapidly rising in Japan, and in addition to four already-approved disease-modifying therapies (DMTs), namely interferon β1b, interferonβ1a, fingolimod and natalizumab, several new DMTs are currently under clinical trials. In this article, emerging DMTs such as alemtuzumab, dimethyl fumarate and teriflunomide as well as fampridine, a novel symptomatic treatment for gait disturbance, and anti-LINGO-1 monoclonal antibody, a possible candidate for future remyelination therapy, will be reviewed. Future treatment strategies such as induction therapy and combined therapy for MS will also be discussed.

元の言語English
ページ(範囲)2031-2037
ページ数7
ジャーナルNihon rinsho. Japanese journal of clinical medicine
72
発行部数11
出版物ステータスPublished - 2014 11 1
外部発表Yes

Fingerprint

Multiple Sclerosis
Therapeutics
Demyelinating Diseases
Gait
Interferons
Japan
Central Nervous System
Monoclonal Antibodies
Clinical Trials
Incidence

ASJC Scopus subject areas

  • Medicine(all)

これを引用

@article{8e2aa6a01b2348bf9291e9b32363ead5,
title = "[Emerging disease-modifying therapies for multiple sclerosis]",
abstract = "Multiple sclerosis(MS) is an inflammatory demyelinating disease of the central nervous system with yet undetermined etiology. The incidence of MS is rapidly rising in Japan, and in addition to four already-approved disease-modifying therapies (DMTs), namely interferon β1b, interferonβ1a, fingolimod and natalizumab, several new DMTs are currently under clinical trials. In this article, emerging DMTs such as alemtuzumab, dimethyl fumarate and teriflunomide as well as fampridine, a novel symptomatic treatment for gait disturbance, and anti-LINGO-1 monoclonal antibody, a possible candidate for future remyelination therapy, will be reviewed. Future treatment strategies such as induction therapy and combined therapy for MS will also be discussed.",
author = "Jin Nakahara",
year = "2014",
month = "11",
day = "1",
language = "English",
volume = "72",
pages = "2031--2037",
journal = "Nihon rinsho. Japanese journal of clinical medicine",
issn = "0047-1852",
publisher = "Nipponrinsho Co., Inc.",
number = "11",

}

TY - JOUR

T1 - [Emerging disease-modifying therapies for multiple sclerosis]

AU - Nakahara, Jin

PY - 2014/11/1

Y1 - 2014/11/1

N2 - Multiple sclerosis(MS) is an inflammatory demyelinating disease of the central nervous system with yet undetermined etiology. The incidence of MS is rapidly rising in Japan, and in addition to four already-approved disease-modifying therapies (DMTs), namely interferon β1b, interferonβ1a, fingolimod and natalizumab, several new DMTs are currently under clinical trials. In this article, emerging DMTs such as alemtuzumab, dimethyl fumarate and teriflunomide as well as fampridine, a novel symptomatic treatment for gait disturbance, and anti-LINGO-1 monoclonal antibody, a possible candidate for future remyelination therapy, will be reviewed. Future treatment strategies such as induction therapy and combined therapy for MS will also be discussed.

AB - Multiple sclerosis(MS) is an inflammatory demyelinating disease of the central nervous system with yet undetermined etiology. The incidence of MS is rapidly rising in Japan, and in addition to four already-approved disease-modifying therapies (DMTs), namely interferon β1b, interferonβ1a, fingolimod and natalizumab, several new DMTs are currently under clinical trials. In this article, emerging DMTs such as alemtuzumab, dimethyl fumarate and teriflunomide as well as fampridine, a novel symptomatic treatment for gait disturbance, and anti-LINGO-1 monoclonal antibody, a possible candidate for future remyelination therapy, will be reviewed. Future treatment strategies such as induction therapy and combined therapy for MS will also be discussed.

UR - http://www.scopus.com/inward/record.url?scp=84922325733&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84922325733&partnerID=8YFLogxK

M3 - Article

C2 - 25518389

AN - SCOPUS:84922325733

VL - 72

SP - 2031

EP - 2037

JO - Nihon rinsho. Japanese journal of clinical medicine

JF - Nihon rinsho. Japanese journal of clinical medicine

SN - 0047-1852

IS - 11

ER -